Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells

KIZ OpenIR > 分子病理学

	Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells
	Lin WM 1; Karsten U 2; Goletz S 2; Cheng RC 3; Cao Y*1; caoy@mail.kiz.ac.cn
	2011
发表期刊	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
卷号	92 期号:2 页码:97-105
合作性质	其它
摘要	P>The cancer-initiating capacity of most malignant tumours is considered to reside in a small subpopulation of cells. Therapeutical interventions should target these cells rather than the tumour mass. Numerous studies have shown that the carbohydrate antigen structure CD176 (Thomsen-Friedenreich antigen, core-1) is present in many types of cancer and absent in normal adult human tissues. In this study, we assessed whether CD176 is co-expressed with CD44 or CD133 [markers of cancer-initiating cells (CIC)] in human lung, breast and liver carcinoma. A variety of human cancer cell lines and surgical specimens of these malignancies were examined. It was found that in most cases the majority of tumour cells stained strongly for CD44 by immunohistochemistry and flow cytometry, whereas CD133 expression was found on a smaller, but varying proportion of cells. Co-expression of CD176 with CD44 was found at a surprisingly high percentage of cancer cells in vitro and in vivo. Co-expression of CD176 with CD133 was also detected, although at a lower rate. Tamoxifen treatment of MDA-435 breast cancer cells enhanced the CD44+/CD176+ phenotype. Evidence is provided through a new sandwich solid-phase enzyme-linked immunosorbent assay (ELISA) suggesting that CD44 is a carrier molecule for CD176 not only in colorectal cancer as previously reported, but also in lung, breast and liver cancer. The expression of CD176 in CIC suggests that it may represent an effective target for tumour therapies.
关键词	Cancer-initiating Cells Cd133 Cd176 Cd44 Co-expression Thomsen-friedenreich Antigen
资助者	This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15).
收录类别	SCI
语种	英语
资助者	This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15).
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/353002/6605
专题	分子病理学科研部门_动物模型与人类重大疾病机理重点实验室
通讯作者	caoy@mail.kiz.ac.cn
作者单位	1.Key Laboratory of Animal Models and Human Disease Mechanisms of CAS and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China 2.Glycotope GmbH, Berlin-Buch, Germany 3.Department of General Surgery, First Affiliated Hospital of Kunming Medical College, Kunming, China
推荐引用方式 GB/T 7714	Lin WM,Karsten U,Goletz S,et al. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells[J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY,2011,92(2):97-105.
APA	Lin WM,Karsten U,Goletz S,Cheng RC,Cao Y*,&caoy@mail.kiz.ac.cn.(2011).Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY,92(2),97-105.
MLA	Lin WM,et al."Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells".INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 92.2(2011):97-105.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2011042505.pdf（479KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文